HKG: 1177

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New...

Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Fineline Cube Aug 4, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s TQB2102,...

Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026

Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (“Tempo Scan”) announced the...

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Fineline Cube Jul 23, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...

Company Drug

Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain

Fineline Cube Jul 15, 2026

Sino Biopharmaceutical (HKG: 1177) announced that TRD205, a Category 1 innovative drug self-developed by its...

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ) has...

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Fineline Cube Jul 8, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE:...

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a...

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Fineline Cube Jun 16, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...

Company Drug

Sino Biopharmaceutical’s Saitanxin Shows 32.4% Response Rate in CDK4/6 Inhibitor-Resistant Breast Cancer at ASCO 2026

Fineline Cube Jun 2, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...

Company Drug

CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026

Fineline Cube Jun 1, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...

Company Drug

LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026

Fineline Cube Jun 1, 2026

LaNova Medicines Ltd., a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented Phase II clinical...

Company Drug

Sino Biopharmaceutical’s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer

Fineline Cube May 29, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...

Company Drug

Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026

Fineline Cube May 29, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well...

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced the presentation of first-in-human Phase I clinical study results...

Company Drug

Jiangsu Chia Tai Tianqing Secures NMPA Priority Review for LM-302 ADC in CLDN18.2-Positive Gastric Cancer

Fineline Cube May 25, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG:...

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Fineline Cube May 24, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced positive results from its Phase III and Phase II...

Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Fineline Cube May 21, 2026

Boehringer Ingelheim (BI) and Sino Biopharmaceutical Ltd (HKG: 1177) jointly announced that Hernexeos (zongertinib) has...

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Fineline Cube May 11, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai...

HKG: 1177

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Sino Biopharmaceutical’s Saitanxin Shows 32.4% Response Rate in CDK4/6 Inhibitor-Resistant Breast Cancer at ASCO 2026

CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026

LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026

Sino Biopharmaceutical’s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer

Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Jiangsu Chia Tai Tianqing Secures NMPA Priority Review for LM-302 ADC in CLDN18.2-Positive Gastric Cancer

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

You Missed

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis